Ascendis Pharma A/S
ASND
Rang in Aktien
#1549
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing... Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
Aktienkurs
$224.87
Zuletzt synchronisiert: 2026-10-16
Marktkapitalisierung
$14.03B
Veränderung (1 Tag)
-0.77%
Veränderung (1 Jahr)
6.83%
Land
DK
Handel Ascendis Pharma A/S (ASND)
Kategorie
Healthcare
EPS für Ascendis Pharma A/S (ASND)
EPS zum June 2026 TTM: $14.35
Laut den aktuellen Finanzberichten und dem Aktienkurs von Ascendis Pharma A/S beträgt das aktuelle EPS des Unternehmens (TTM) $14.35. Am Ende des Jahres 2024 betrug das EPS $-6.79 ein Rückgang im Vergleich zu dem EPS von 2023, das $-9.45 betrug.
EPS-Verlauf von Ascendis Pharma A/S von 2012 bis 2026
EPS am Ende jedes Jahres
| Jahr | EPS | ändert |
|---|---|---|
| 2026 (TTM) | $14.35 | -437.71% |
| 2025 | $-4.25 | -37.49% |
| 2024 | $-6.79 | -28.11% |
| 2023 | $-9.45 | -15.28% |
| 2022 | $-11.16 | 40.15% |
| 2021 | $-7.96 | -21.06% |
| 2020 | $-10.08 | 91.63% |
| 2019 | $-5.26 | 44.45% |
| 2018 | $-3.64 | -17.50% |
| 2017 | $-4.42 | 62.66% |
| 2016 | $-2.71 | 79.86% |
| 2015 | $-1.51 | 118.83% |
| 2014 | $-0.69 | -231.97% |
| 2013 | $0.52 | 230.13% |
| 2012 | $0.16 | 0.00% |
EPS für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | EPS | EPS-Differenz | Land |
|---|---|---|---|
| $17.32 | 20.68% |
US
|
|
| $-7.98 | -155.60% |
US
|
|
| $-5.29 | -136.86% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | 93.28% |
NL
|
